Sign In
Buy AKBA
$0.97
+0.0333 (+3.56%)
At Close: Jun 03, 2026
Akebia Therapeutics: A Clear Path To A Blockbuster CKD-Anemia Treatment (NASDAQ:AKBA)
02:13am, Monday, 01'st Jun 2020
Akebia has taken a significant step towards securing approval for Vadadustat, its potential blockbuster treatment for anemia in CKD sufferers. Data from the pha
Suzuki Motor : April 2020 Automobile Production, Sales, and Export Figures (Preliminary) | MarketScreener
08:03am, Thursday, 28'th May 2020Edited Transcript of AKBA earnings conference call or presentation 5-May-20 12:30pm GMT
06:38am, Wednesday, 27'th May 2020
Q1 2020 Akebia Therapeutics Inc Earnings Call
Akebia Therapeutics to Present at Jefferies Virtual Global Healthcare Conference
12:00pm, Tuesday, 26'th May 2020
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that its President and Chief Executive
Akebia Therapeutics Announces Change to Virtual Annual Meeting of Stockholders
08:05pm, Thursday, 21'st May 2020
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that due to the public health impact of
Akebia Therapeutics Inc (NASDAQ: AKBA) Q1 2020 Earnings Call Transcript | AlphaStreet
05:03pm, Thursday, 21'st May 2020
Final earnings conference call transcript of Akebia Therapeutics Inc. - AKBA stock
Akebia Therapeutics Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
08:05pm, Tuesday, 19'th May 2020
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the underwriters of its previously
Tracking David Abrams' Abrams Capital Management Portfolio - Q1 2020 Update
06:34am, Tuesday, 19'th May 2020
David Abrams’ 13F portfolio value decreased this quarter from $3.22B to $2.54B. The number of positions increased from 21 to 22. Abrams Capital Management added
Our Chief Picks In Pharma
04:01am, Tuesday, 19'th May 2020
Recent results in Pharma show that there are some highly resilient plays for the COVID-19 environment. Now is a good time to take advantage of these extremely h
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, announced today that its c
Consonance Capital Management LP Buys Akebia Therapeutics Inc, Sarepta Therapeutics Inc, ...
12:00am, Friday, 15'th May 2020Akebia Therapeutics, Inc. (AKBA) Shares March Higher, Can It Continue?
03:37pm, Wednesday, 13'th May 2020
As of late, it has definitely been a great time to be an investor in Akebia Therapeutics, Inc. (AKBA).
